Given the strong first quarter results and expectations for the remainder of the year, the Company is updating its full year 2023 guidance ranges as noted below, including an
MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the establishment of a Strategic Advisory
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.23) per share. This is a 8 percent increase over losses of $(0.25) per share from the same period last year.
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that